CA3095986A1 - Axl-specific antibodies for cancer treatment - Google Patents

Axl-specific antibodies for cancer treatment Download PDF

Info

Publication number
CA3095986A1
CA3095986A1 CA3095986A CA3095986A CA3095986A1 CA 3095986 A1 CA3095986 A1 CA 3095986A1 CA 3095986 A CA3095986 A CA 3095986A CA 3095986 A CA3095986 A CA 3095986A CA 3095986 A1 CA3095986 A1 CA 3095986A1
Authority
CA
Canada
Prior art keywords
antibody
adc
seq
region
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3095986A
Other languages
English (en)
French (fr)
Inventor
Maarten JANMAAT
Esther BREIJ
Ulf Forssmann
Tahamtan Ahmadi
Julia BOSHUIZEN
Daniel PEEPER
Nora Pencheva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genmab AS
Original Assignee
Genmab AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab AS filed Critical Genmab AS
Publication of CA3095986A1 publication Critical patent/CA3095986A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3095986A 2018-04-10 2019-04-10 Axl-specific antibodies for cancer treatment Pending CA3095986A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862655417P 2018-04-10 2018-04-10
US62/655,417 2018-04-10
PCT/EP2019/059171 WO2019197506A1 (en) 2018-04-10 2019-04-10 Axl-specific antibodies for cancer treatment

Publications (1)

Publication Number Publication Date
CA3095986A1 true CA3095986A1 (en) 2019-10-17

Family

ID=66182546

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3095986A Pending CA3095986A1 (en) 2018-04-10 2019-04-10 Axl-specific antibodies for cancer treatment

Country Status (10)

Country Link
US (1) US20210070869A1 (enExample)
EP (1) EP3774904A1 (enExample)
JP (1) JP7681401B2 (enExample)
CN (1) CN112218895A (enExample)
AU (1) AU2019250443A1 (enExample)
CA (1) CA3095986A1 (enExample)
EA (1) EA202092448A1 (enExample)
IL (1) IL277861A (enExample)
MA (1) MA52657A (enExample)
WO (1) WO2019197506A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019505520A (ja) 2016-01-13 2019-02-28 ゲンマブ エー／エス 抗体およびその薬物コンジュゲートの製剤
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
WO2021013746A1 (en) * 2019-07-19 2021-01-28 Genmab A/S Axl antibody-drug conjugates for use in treating cancer
AU2021208433A1 (en) * 2020-01-14 2022-07-14 Uswm Ct, Llc Method of treatment of cancer or tumour
US11807688B2 (en) * 2020-02-28 2023-11-07 Les Laboratoires Servier Anti-AXL antibodies and compositions
EP4259200A1 (en) * 2020-12-11 2023-10-18 Boehringer Ingelheim International GmbH Formulation for multi-purpose application
AU2021451307A1 (en) * 2021-06-16 2024-02-01 Shanghai Sinobay Biotechnology Co., Ltd. Antibody targeting axl protein and antigen binding fragment thereof, preparation method therefor and use thereof
EP4359439A1 (en) 2021-06-24 2024-05-01 Yeda Research and Development Co. Ltd Combination therapy for the treatment of cancer comprising an anti-egfr antibody and an axl-inhibitor
IL289525B2 (en) * 2021-12-30 2023-03-01 B G Negev Technologies And Applications Ltd At Ben Gurion Univ Conjugated antibodies for cancer treatment
KR20250151447A (ko) * 2023-02-22 2025-10-21 레졸루트 사이언스, 인크. 종양-관련 대식세포를 표적화하기 위한 조성물 및 방법
WO2024178140A1 (en) * 2023-02-22 2024-08-29 Resolute Science, Inc. Compositions and methods for targeting tumor-associated macrophages
WO2026132321A1 (en) 2024-12-19 2026-06-25 Institut National de la Santé et de la Recherche Médicale Axl inhibitors for the treatment of mastocytosis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
CN101918452A (zh) 2007-11-15 2010-12-15 中外制药株式会社 与Anexelekto结合的单克隆抗体及其利用
CN102459344A (zh) 2009-05-15 2012-05-16 中外制药株式会社 抗axl抗体
CN103080136B (zh) 2010-06-18 2015-08-12 霍夫曼-拉罗奇有限公司 抗Axl抗体及使用方法
AU2012273955A1 (en) 2011-06-22 2014-01-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Axl antibodies and uses thereof
WO2012175691A1 (en) 2011-06-22 2012-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
EP2589609A1 (en) 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
US9879061B2 (en) 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
US20160106861A1 (en) 2013-04-26 2016-04-21 Spirogen Sarl Axl antibody-drug conjugate and its use for the treatment of cancer
GB201410825D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
DK3169706T3 (da) 2014-07-11 2020-03-09 Genmab As Antistoffer, der binder axl
WO2016097370A2 (en) * 2014-12-18 2016-06-23 Bergen Teknologioverføring As Anti-axl antagonistic antibodies
CA2991805A1 (en) * 2015-07-10 2017-01-19 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment
ES2896079T3 (es) * 2016-02-26 2022-02-23 Ono Pharmaceutical Co Fármaco para la terapia del cáncer, caracterizado por la administración de la combinación entre un inhibidor de Axl y un inhibidor del punto de control inmunitario
US20190233522A1 (en) 2016-07-08 2019-08-01 Genmab A/S New dosage regimens for antibody drug conjugates based on anti-axl antibodies

Also Published As

Publication number Publication date
MA52657A (fr) 2021-02-17
EP3774904A1 (en) 2021-02-17
US20210070869A1 (en) 2021-03-11
IL277861A (en) 2020-11-30
WO2019197506A1 (en) 2019-10-17
CN112218895A (zh) 2021-01-12
JP7681401B2 (ja) 2025-05-22
AU2019250443A1 (en) 2020-10-22
WO2019197506A9 (en) 2019-12-05
JP2021521143A (ja) 2021-08-26
EA202092448A1 (ru) 2021-03-05

Similar Documents

Publication Publication Date Title
US20210070869A1 (en) Axl-specific antibodies for cancer treatment
JP7204651B2 (ja) 抗体－薬物コンジュゲートの製剤及びその凍結乾燥方法
EP3347054B1 (en) Dosing regimens for anti-tf-antibody drug-conjugates
KR20240096827A (ko) 암의 치료에 클라우딘 18.2에 대한 항체를 이용하는 치료법
TWI916314B (zh) 使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法
US20190233522A1 (en) New dosage regimens for antibody drug conjugates based on anti-axl antibodies
CA3193104A1 (en) Pharmaceutical composition comprising antibody-drug conjugate, and use of pharmaceutical composition
CN112203695A (zh) 用基于铂的试剂和抗组织因子抗体-药物偶联物的组合治疗癌症的方法
US20210393793A1 (en) Axl-specific antibodies for treatment of non-small cell lung cancer
TW202333797A (zh) 含有抗ceacam5抗體-藥物接合物及抗vegfr-2抗體之抗腫瘤組合
KR102606179B1 (ko) 암의 치료를 위한 abx196을 포함하는 조합물
TW202019405A (zh) 用於治療晚期非小細胞肺癌之標靶性TGF-β抑制之組合療法
TW202003577A (zh) 用於在未曾接受過治療之個體治療癌症的標靶性TGF-β抑制之給藥方案
US20220273809A1 (en) Axl antibody-drug conjugates for use in treating cancer
BR112019020507A2 (pt) agente de alvejamento de erbb-2 e um anticorpo bispecífico com locais de ligação de antígenos que ligam um epítopo em uma parte extracelular de erbb-2 e erbb-3 para tratamento de um indivíduo com um tumor positivo erbb-2, erbb-2 / erbb-3
AU2024298986C1 (en) Pharmaceutical composition containing anti-nectin4 antibody-drug conjugate and anti-pd-1 antibody and use thereof
TW202515906A (zh) 治療中風之方法
WO2023185732A1 (zh) 包含抗Claudin18.2和CD3双特异性抗体的制剂及其制备方法和用途
HK40112971A (en) Egfr and lag3 dual targeted bispecific antibody and uses thereof
HK40052936B (en) Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
EA049767B1 (ru) Фармацевтическая композиция, содержащая конъюгат антитела и лекарственного средства, и применение фармацевтической композиции
HK40052936A (en) Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
HK40045175A (en) Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240404

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241224

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241224

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241224

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250922

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260305

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260305